{'52WeekChange': 0.2427746,
 'SandP52WeekChange': 0.0644362,
 'address1': '640 Lee Road',
 'address2': 'Suite 200',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.23,
 'askSize': 2200,
 'averageDailyVolume10Day': 1466462,
 'averageVolume': 705582,
 'averageVolume10days': 1466462,
 'beta': 1.16,
 'beta3Year': None,
 'bid': 2.12,
 'bidSize': 1000,
 'bookValue': 1.391,
 'category': None,
 'circulatingSupply': None,
 'city': 'Wayne',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 2.27,
 'dayLow': 2.08,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -0.33,
 'enterpriseToRevenue': 5.859,
 'enterpriseValue': 25608642,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 1.76,
 'fiftyTwoWeekHigh': 3.34,
 'fiftyTwoWeekLow': 0.7,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 26251036,
 'forwardEps': -1.48,
 'forwardPE': -1.4527028,
 'fromCurrency': None,
 'fullTimeEmployees': 75,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.10009,
 'heldPercentInstitutions': 0.84812,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/aclaristx.com',
 'longBusinessSummary': 'Aclaris Therapeutics, Inc., a biopharmaceutical '
                        'company, focuses on developing drug candidates for '
                        'immuno-inflammatory diseases in the United States. It '
                        'operates in two segments, Therapeutics and Contract '
                        'Research. The company offers ESKATA, a formulation of '
                        'high-concentration hydrogen peroxide topical solution '
                        'for raised seborrheic keratosis, a common '
                        'non-malignant skin tumor. It is also developing '
                        'A-101, a high-concentration formulation of hydrogen '
                        'peroxide that is in Phase III clinical trial for '
                        'common warts; and ATI-501 and ATI-502 Janus kinase '
                        '(JAK) inhibitors, which are in Phase II clinical '
                        'trials for alopecia areata (AA) and other '
                        'dermatological indications. In addition, the '
                        "company's products under development include ATI-450 "
                        'an investigational oral, novel, small molecule '
                        'selective MK2 inhibitor compound for the treatment of '
                        'rheumatoid arthritis; ATI-1777 soft inhibitor for '
                        'atopic dermatitis; and ATI-2138, an investigational '
                        'oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for '
                        'the treatment of psoriasis inflammatory bowel '
                        'disease. Further, it provides contract research '
                        'services. Aclaris Therapeutics, Inc. has a license '
                        'and collaboration agreement with Rigel '
                        'Pharmaceuticals, Inc. for the development and '
                        'commercialization of JAK inhibitors. The company was '
                        'founded in 2012 and is headquartered in Wayne, '
                        'Pennsylvania.',
 'longName': 'Aclaris Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 90012552,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_216879819',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -101589000,
 'nextFiscalYearEnd': 1640908800,
 'open': 2.19,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.01,
 'phone': '484 324 7933',
 'previousClose': 2.24,
 'priceHint': 4,
 'priceToBook': 1.5456506,
 'priceToSalesTrailing12Months': 20.593126,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 2.27,
 'regularMarketDayLow': 2.08,
 'regularMarketOpen': 2.19,
 'regularMarketPreviousClose': 2.24,
 'regularMarketPrice': 2.19,
 'regularMarketVolume': 645287,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 41832200,
 'sharesPercentSharesOut': 0.0327,
 'sharesShort': 1370272,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1743956,
 'shortName': 'Aclaris Therapeutics, Inc.',
 'shortPercentOfFloat': 0.0344,
 'shortRatio': 1.38,
 'startDate': None,
 'state': 'PA',
 'strikePrice': None,
 'symbol': 'ACRS',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -3.365,
 'twoHundredDayAverage': 1.4174173,
 'volume': 645287,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.aclaristx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '19087'}